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Abstract: Two series of thiosemicarbazone-based iron chelators (twenty-seven 
compounds) were designed and synthesized using a microwave-assisted approach. 
Quinoline and halogenated phenyl were selected as parent scaffolds on the basis of a 
similarity search. The lipophilicity of the synthesized compounds was measured using 
HPLC and then calculated. Primary in vitro screening of the synthesized compounds was 
performed against eight pathogenic fungal strains. Only a few compounds showed 
moderate activity against fungi, and (E)-2-(quinolin-2-ylvinyl)-N,N-dimethylhydrazine-
carbothioamide appeared to be more effective than fluconazole against most of the fungal 
strains tested. Antiproliferative activity was measured using a human colon cancer cell line 
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(HCT-116). Several of the tested compounds showed submicromolar antiproliferative 
activity. Compounds were also tested for their activity related to the inhibition of 
photosynthetic electron transport (PET) in spinach (Spinacia oleracea L.) chloroplasts. The 
structure-activity relationships are discussed for all of the compounds. 
Keywords: thiosemicarbazones; lipophilicity; photosynthetic electron transport inhibition; 
spinach chloroplasts; iron chelators; in vitro antifungal activity; in vitro anticancer activity 
 
1. Introduction 
Iron is an element of great importance for virtually all living organisms. It is present in various 
biological processes such as metabolic pathways, reproduction or photosynthesis. On the basis of its 
importance, the iron-sulphur theory of the origin of life has been proposed [1,2]. Despite being so 
pervasive, iron rarely exists alone or in the form of simple cations. It is commonly chelated by larger 
organic molecules such as porphyrin. This form is present in hemoglobin or in most of the metabolic 
enzymes of cytochrome P450 [3]. Clearly, all living organisms have their ways of acquiring and 
managing such an important element. Any alteration of or damage to the iron metabolism system may 
lead to serious diseases. In humans, this may cause hemochromatosis or iron deficiency anemia [4]. As 
a target for therapy, iron is used mainly in the treatment of iron overload using iron chelators such as 
deferoxamine (DFO, also known as desferrioxamine B) [5]. More recently, iron chelators have been 
proposed for cancer treatment [5–10] because rapidly proliferating cancer cells have a higher demand 
for this element compared to the normal cells [5,11]. Although the exact mechanism of the anticancer 
activity of iron chelators remains unknown, several possible modes of action can be implemented,  
e.g., the inhibition of iron uptake [12] and the inhibition of ribonucleotide reductase (RR) [13] or the 
formation of reactive oxygen species (ROS) [14]. 
Other potential therapeutic or agricultural application of iron chelators may be derived from 
processes or pathways that are dependent on iron in pathological organisms. Fungi and bacteria  
require an appropriate amount of iron for correct growth, and apparently to develop their resistance to 
drugs [15,16]. Pathogenic microbes have evolved their unique way of acquiring this important metal 
from a host organism through the overexpression of Fe receptors or the utilization of siderophores [17]. If 
the iron level is reduced, fungi lose some of their virulence and have a decreased potency to invade the 
epithelium. Hence, lactoferrin and deferoxamine have been tested for their antifungal potency. Early 
attempts have consisted in the co-administration of lactoferrin with conventional antifungals such as 
amphotericin B [18,19]. DFO was tested as an ancillary drug with amphotericin B in antifungal 
therapy in a clinical trial [20,21]. The study was terminated prematurely due to an increased mortality 
in patients who had taken DFO when compared to those who had taken a placebo. However, this 
seems to be an effect of the more complex prerequisites connected with the unknown site of 
administration of DFO rather than with synergic toxicity. Nevertheless, this is a trigger to search for 
structurally new iron chelators with an antifungal activity. Several reports describing the synthesis and 
antifungal activity of thiosemicarbazones have been published [22–26]. Li et al. described a series of 
benzyl thiosemicarbazones whose substitution with a chlorine atom triggered the activity of mushroom 
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tyrosinase [27]. Moreover, chlorine derivatives of benzaldehyde 4-phenyl-3-thiosemicarbazone and 
their cyclization products were tested against Toxoplasma gondii and several bacterial strains [28]. 
Some of these derivatives were more active than chloramphenicol and rifampicin. 
In this paper, some disubstituted benzaldehyde thiosemicarbazones are described along with their 
anticancer and antifungal activity. These structures were tested on the basis of a former study on 
antifungal compounds [29–33] and quinolone-based thiosemicarbazones with anticancer activity [34]. 
Figure 1 illustrates the fragment-based similarity of the compounds investigated with known and 
effective iron chelators [5,35–37]. The design of compounds with polypharmacological activity was 
the aim of our investigation. Such compounds may be of great value in anticancer therapy where 
fungal infections are very common. Furthermore, these compounds, due to their simple and cheap 
synthesis, are suitable for agricultural use. However, antifungal agents such as azoles used for crop 
protection raise some concerns, e.g., triggering resistance [38] and have a negative impact on the 
environment. In fact, iron is also important in plants where it plays a crucial role in photosystems I and 
II as a part of ferredoxin [39] and cytochrome b559 [40–43]. Taking this aspect into account, 
thiosemicarbazone iron chelators may exert some unwanted effects on the green parts of plants. Thus, 
the compounds prepared for the inhibition of photosynthetic electron transport were also tested. 
Figure 1. (A) Structures of known iron chelators 3-AP [5], 311 [35], Dp44mT [36,37].  
(B) investigated benzylidenethiosemicarbazones 3a–o, quinolinylvinylthiosemicarbazones 
4a–l. 
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2. Results and Discussion 
2.1. Chemistry 
Compounds 3a–o were obtained as shown in Scheme 1. Microwave irradiation was found to be 
helpful for enhancing the yield of the syntheses and the purity of the final products (the purity of all of 
the compounds was assessed using HPLC and was higher than 98%, while the overall average yield 
exceeded 80%). All of the synthesized compounds were in the E-configuration, which was confirmed 
using 1H-NMR spectroscopy (the signal of the NH group was in the 10–11 ppm range, in comparison 
to Z-isomer, which possesses a characteristic NH signal in the 14–15 ppm range), the COSY and 
NOESY experiments and by crystal structure as was reported recently [44]. Exemplary spectra are 
available in Supplementary Material for this article.  
Scheme 1. Synthesis of the discussed benzylidenethiosemicarbazones 3a–o and 
quinolinylvinylthiosemicarbazones 4a–l. 
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2.2. Lipophilicity 
Lipophilicity is a property that has a major effect on absorption, distribution, metabolism, excretion 
and toxicity properties as well as on pharmacological activity because drugs cross biological 
membranes through passive transport, which is strongly dependent on their lipophilicity. Lipophilicity 
has been studied and applied as an important drug property for decades. The lipophilicity of the 
compounds studied was determined using RP-HPLC as a capacity factor logarithm (log k) and 
calculated as log P/Clog P using two commercially available software programs (ChemOffice and 
ACD/LogP) [45,46]. The results for benzylidenethiosemicarbazones 3a–o are shown in Table 1, they 
are summarized for quinolinylvinylthiosemicarbazones 4a–l in Table 2 and are illustrated for both 
series in Figure 2. 
Reversed phase high performance liquid chromatography (RP-HPLC) methods have become 
popular and are widely used for lipophilicity measurements. The general procedure is the measurement 
of the directly accessible retention time under isocratic conditions using varying amounts of methanol 
as an organic modifier in the mobile phase using RP columns and calculating the logarithm of the 
capacity factors (log k). Log k is the logarithm of the capacity factors in chromatographic approaches 
that is related to the partitioning of a compound between a mobile and a (pseudo-)stationary phase. 
Log k is used as the lipophilicity index converted to log P scale. 
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Table 1. Structure of aryl compounds 3a–o and comparison of the calculated lipophilicities 
(log P/Clog P) with determined log k values.  
N
H
N N
R3
R1
S
R2
Comp. R1 R2 R3 log k 
log P/Clog P 
ChemOffice 
log P 
ACD/LogP 
3a 2,3-Cl H H 0.6892 2.81/3.473 3.22 ± 0.38 
3b 2,3-Cl H CH3 0.7357 3.33/3.177 3.14 ± 0.59 
3c 2,3-Cl CH3 CH3 0.7214 3.71/3.533 3.11 ± 0.60 
3d 2,3-Cl H C2H5 0.7958 3.67/3.706 3.68 ± 0.59 
3e 2,3-Cl H C6H5 0.9230 5.00/5.266 4.90 ± 0.59 
3f 3,4-Cl H H 0.6974 2.81/3.473 3.28 ± 0.38 
3g 3,4-Cl H CH3 0.7563 3.33/3.177 3.21 ± 0.59 
3h 3,4-Cl CH3 CH3 0.7555 3.71/3.533 3.17 ± 0.60 
3i 3,4-Cl H C2H5 0.8415 3.67/3.706 3.74 ± 0.59 
3j 3,4-Cl H C6H5 0.9774 5.00/5.266 4.96 ± 0.59 
3k 4-Br H H 0.6580 2.53/2.952 2.79 ± 0.39 
3l 4-Br H CH3 0.6993 3.05/2.734 2.72 ± 0.61 
3m 4-Br CH3 CH3 0.6784 3.42/3.090 2.68 ± 0.62 
3n 4-Br H C2H5 0.7568 3.39/3.263 3.25 ± 0.61 
3o 4-Br H C6H5 0.8772 4.71/4.823 4.47 ± 0.61 
Commercially available chemical software does not resolve the various lipophilicity values of 
individual positional isomers, etc. The software calculates lipophilicity contributions according to 
different internal databases/libraries and uses different approaches. It can be concluded that for small, 
highly functionalized molecules with many heteroatoms, a number of intermolecular forces and 
intramolecular interactions are typical. The more of these interactions that can be expected, the less the 
predictability of common software can be, thus experimental lipophilicity determination is of great 
importance. Therefore, we decided to perform our measurements using the water-methanol system as 
the mobile phase. Log k derived from RP-HPLC retention factors and computational log P values are 
given in the manuscript and biological data are related to log k data because log k data specify 
lipophilicity within the series of compounds more precisely than the available chemical software. 
The results obtained with all the compounds show that the experimentally-determined 
lipophilicities (log k) of the compounds discussed are relatively in accordance with the calculated 
values of compounds 3a–o and 4a–l as is shown in Figure 2. The minimum match of experimental (log k) 
versus calculated (log P) values was found for ChemOffice. Generally, benzylidenethiosemicarbazones 
3a–o showed a higher match (see Figure 2A) than quinolinylvinylthiosemicarbazones 4a–l (see  
Figure 2B), which indicates inter- and intramolecular interactions in the last mentioned series. 
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Table 2. Structure of heteroaryl compounds 4a–l and comparison of calculated 
lipophilicities (log P/Clog P) with determined log k values.  
R1
N
H
N N
R3
S
R2
Comp. R1 R2 R3 log k 
log P/Clog P 
ChemOffice 
log P 
ACD/LogP 
4a N  H CH3 0.6329 2.73/1.968 2.06 ± 0.59 
4b N  CH3 CH3 0.6184 3.10/2.114 2.02 ± 0.60 
4c N  H, C2H5 0.6892 3.06/2.497 2.59 ± 0.59 
4d N  H C6H5 0.7553 4.39/4.057 3.81 ± 0.59 
4e N
OH  
H CH3 0.6236 2.34/2.064 1.85 ± 0.84 
4f N
OH  
CH3 C6H5 0.5927 2.71/2.163 1.81 ± 0.85 
4g N
OH  
H C2H5 0.6810 2.67/2.593 2.38 ± 0.84 
4h N
OH  
H C6H5 0.7548 4.00/4.153 3.60 ± 0.84 
4i N OH
 
H CH3 0.6193 1.91/2.131 1.62 ± 1.09 
4j N OH
 
CH3 CH3 0.5831 2.29/2.163 1.58 ± 1.10 
4k N OH
 
H C2H5 0.6539 2.25/2.660 2.15 ± 1.09 
4l N OH
 
H C6H5 0.6748 3.58/4.220 3.37 ± 1.09 
Lipophilicity calculations of these small and highly functionalized molecules do not cover inter- 
and intramolecular interactions that can be found by experimental lipophilicity determination. As was 
expected, quinolinylvinylthiosemicarbazones 4a–l showed a lower lipophilicity (log k) than 
benzylidene-thiosemicarbazones 3a–o. Within the series of benzylidenethiosemicarbazones, the 
determined log k values increased as follows: 4-Br (3k–o) < 2,3-Cl (3a–e) < 3,4-Cl (3f–j), while 
within the series of quinolinylvinylthiosemicarbazones, the determined log k values increased in the 
following order: 7-hydroxyquinolin-8-yl (4i–l) < 8-hydroxyquinolin-2-yl (4e–h) < quinoline-2-yl (4a–d). 
The influence of R2 and R3 substituents on lipophilicity is as follows: 2H < 2CH3 < H, CH3 < H, C2H5 < H, 
C6H5. Based on the above-mentioned data, it can be assumed that compounds 4e–l are possible 
tautomeric isomers. This seems to be in agreement with our former findings [47]. Therefore, it can be 
concluded that log k values specify lipophilicity within individual series of the compounds studied 
more precisely than the calculated log P/Clog P data. 
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Figure 2. Comparison of log P/Clog P data calculated using two programs with log k 
values found experimentally. (A) match of calculated data with log k values of 3a–o found 
experimentally; (B) match of calculated data with log k values of 4a–l found experimentally. 
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2.3. Biological Activities 
The compounds under investigation can be divided into two groups based on their chemical 
structure: Group 1 included benzylidenethiosemicarbazones 3a–o and Group 2 contained 
quinolinylvinylthiosemicarbazones 4a–l. The compounds showed a wide range of biological activities 
and some interesting structure-activity relationships were observed. All of the results are summarized 
in Table 3. 
2.3.1. Inhibition of Photosynthetic Electron Transport (PET) in Spinach Chloroplasts 
The activity of all of the evaluated derivatives related to the inhibition of photosynthetic electron 
transport (PET) in spinach (Spinacia oleracea L.) chloroplasts was moderate or rather low relative to 
the standard (see Table 3). Diuron® (DCMU), a marketed herbicide with its activity mechanism 
directed to photosystem II, was used as the standard. The compounds within Group 2 could not be 
evaluated for their structure-activity relationships because the majority of these compounds showed no 
PET-inhibiting activity. (E)-2-(3,4-Dichlorobenzylidene)-N-methylhydrazinecarbothioamide (3g) 
expressed the highest PET-inhibiting activity (IC50 = 135.6 µmol/L) within Group 1. 
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Table 3. IC50 [μmol/L] values related to PET inhibition in spinach chloroplasts of the 
substituted thiosemicarbazones in comparison with 3-(3,4-dichlorophenyl)-1,1-dimethylurea 
(DCMU) as the standard; in vitro antifungal activity (IC80/IC50 [μmol/L]) of compounds 
compared to fluconazole (FLU) as the standard; in vitro antiproliferative activity IC50 
[μmol/L] of compounds compared to doxorubicin as the standard. ND = not determined 
due to precipitation during the experiment or interaction with 2,6-dichlorophenol-
indophenol (DCPIP). 
Comp. 
PET 
IC50 
1,2 MIC (a IC80 / b IC50) [µmol/L] 
HCT-116 
IC50 
CA a CT a CK a CG a TB a AF b AC b TM b 
24 h 
48 h 
24 h 
48 h 
24 h 
48 h 
24 h 
48 h 
24 h 
48 h 
24 h 
48 h 
24 h 
48 h 
72 h 
120 h 
3a ND 125 125 125 125 125 125 125 125 41.5 ± 1.7 3 
3b 170.1 500 500 500 500 500 500 500 500 >60 
3c ND 125 125 125 125 125 125 125 125 - 
3d ND 500 500 500 500 500 500 500 500 58.5 ± 0.2 3 
3e 499.3 125 125 125 125 125 125 125 125 >60 
3f 283.3 500 500 500 500 500 500 500 500 46.0 ± 0.9 
3g 135.6 125 125 125 125 125 125 125 125 55.5 ± 6.2 
3h 329.3 
15.62 
31.25 
500 
500 
500 
500 
500 
500 
125 
500 
>500 
>500 
>500 
>500 
31.25 
62.50 
47.0 ± 1.3 
3i 280.2 500 500 500 500 500 500 500 500 48.5 ± 2.8 
3j 425.9 125 125 125 125 125 125 125 125 >60 
3k 586.4 
500 
500 
500 
500 
500 
500 
500 
500 
500 
500 
500 
500 
500 
500 
500 
500 >60 
3l ND 500 500 500 500 500 500 500 500 >60 
3m 594.6 
62.50 
250 
500 
500 
500 
500 
500 
500 
15.62
62.50 
500 
500 
500 
500 
62.50 
62.50 
47.5 ± 2.4 
3n ND 500 500 500 500 500 500 500 500 >60 3 
3o ND 500 500 500 500 500 500 500 500 >60 
4a ND 500 500 500 500 500 500 500 500 >25 
4b 1368 
1.95 
1.95 
1.95 
7.81 
3.90 
3.90 
1.95 
1.95 
1.95 
1.95 
3.90 
3.90 
3.90 
3.90 
3.90 
3.90 
4.86 ± 1.48 3 
4e 302 125 125 125 125 125 125 125 125 1.71 ± 0.34 3 
4f ND 500 500 500 500 500 500 500 500 - 
4h ND 
125 
125 
125 
125 
125 
125 
125 
125 
125 
125 
125 
125 
125 
125 
125 
125 24.97 ± 4.29 
3
4i ND 
500 
500 
500 
500 
500 
500 
500 
500 
500 
500 
500 
500 
500 
500 
500 
500 >25 
3 
4j 520.4 
125 
250 
250 
250 
250 
250 
125 
125 
125 
250 
250 
250 
250 
250 
125 
125 
20.75 ± 5.34 3
4k ND 
500 
500 
500 
500 
500 
500 
62.50
500 
500 
500 
500 
500 
500 
500 
62.50 
62.50 
>25 3 
4l ND 
31.25 
62.50 
125 
125 
31.25
125 
15.62
31.25 
15.62
125 
125 
125 
15.62
62.50 
15.62 
15.62 
16.28 ± 1.69 3
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Table 3. Cont. 
Comp. 
PET 
IC50 
1,2 MIC (a IC80 / b IC50) [µmol/L] 
HCT-116 
IC50 
CA a CT a CK a CG a TB a AF b AC b TM b 
24 h 
48 h 
24 h 
48 h 
24 h 
48 h 
24 h 
48 h 
24 h 
48 h 
24 h 
48 h 
24 h 
48 h 
72 h 
120 h 
DCMU 1.9 - - - - - -  - - 
FLU - 
0.06 
0.12 
0.12 
125 
3.91 
15.62
0.98 
3.91 
0.24 
0.48 
125 
125 
125 
125 
1.95 
3.91 
- 
DXR - - - - - - - - - 10 ± 1.1 
1 The MIC determination was performed according to the CLSI reference protocol: a M27-A2 for 
yeasts (IC80 value) and b M38-A for moulds (IC50 value); CA = Candida albicans, CT = Candida 
tropicalis, CK = Candida krusei, CG = Candida glabrata, TB = Trichosporon beigelii,  
AF = Aspergillus fumigatus, AC = Absidia corymbifera, and TM = Trichophyton mentagrophytes.  
2 All compounds were tested for short and long term activity. When inactive only one value is 
presented. 3 Synthesis and anticancer activity described elsewhere [34,44]. HCT-116 human colon 
cancer cells, DXR- doxorubicin as the standard. 
Figure 3 illustrates the dependence of the PET-inhibiting activity, expressed by the negative 
logarithm of the log (1/IC50 [mol/L]) value on the lipophilicity, expressed as log k, of 
benzylidenethiosemicarbazones 3a–o. Although the dependence seems to be clear, it is not possible to 
draw a simple relationship. The regression with parabolic function did not provide a good correlation. 
This suggests that lipophilicity is only one of the important factors. Nevertheless, despite the relatively 
low inhibitory activity of the compounds studied, the correlations between log (1/IC50) and the 
lipophilicity showed a bilinear course: in the range of log k = 0.6580 (3k) to log k = 0.7563 (3g)  
PET-inhibiting activity linearly increased with increasing compound lipophilicity; however, with a further 
increase in lipophilicity, the inhibitory activity declined. Generally, 4-Br-benzylidenethiosemi-
carbazones 3k–o showed the worst PET inhibition. Disubstitution by 3,4-Cl of the benzylidene ring 
seems to be more advantageous than disubstitution by 2,3-Cl of the benzylidene moiety. It can be 
stated that within the 3,4-Cl-benzylidenethiosemicarbazones 3f–j N,N-disubstitution caused a decrease 
in PET inhibition (compare 3g/3h). Based on these facts, it can be concluded that PET-inhibiting 
activity would probably be negatively influenced by bulky or long-chain alkyls or by the substitution 
of the second hydrogen of the terminal amino moiety. 
2.3.2. In Vitro Antifungal Susceptibility Testing 
The antifungal activity of the compounds studied was tested against several pathogenic fungi and 
the results of the screening are shown in Table 3. The values are correlated to the standard drug 
fluconazole. The majority of the compounds studied appeared to be inactive against the fungal strains 
tested. Nevertheless, some of them, 3h, 3m, and 4l, showed moderate activity, especially against 
Candida albicans, Trichosporon beigelii, and Trichophyton mentagrophytes. (E)-2-(Quinolin-2-
ylvinyl)-N,N-dimethylhydrazinecarbothioamide (4b) expressed the strongest activity among all of the 
compounds tested. Compound 4b was more active than fluconazole against Aspergillus fumigatus and 
Absidia corymbifera. Furthermore, this compound showed an interesting pattern of long terminal 
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activity and was active at a comparable level for 24 h and 48 h protocols. The (Candida tropicalis and 
Candida krusei) activity of fluconazole decreased significantly for some fungi. 
Figure 3. Relationships between PET inhibition log (1/IC50) [mol/L] in spinach 
chloroplasts and lipophilicity of studied benzylidenethiosemicarbazones 3a–o. 
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As most compounds showed only a moderate or no activity, no thorough structure-activity 
relationships could be established. According to the results presented in Table 3, it can be concluded 
that compounds with a quinoline nucleus, i.e., quinolinylvinylthiosemicarbazones (Group 2) seem to be 
more effective antifungals than Group 1, i.e., benzylidenethiosemicarbazones. Based on recent results [32],  
it was expected that 8-hydroxyquinolinylvinylthiosemicarbazones would possess a higher antifungal 
activity than antifungal tests showed. It can be stated, contrary to PET-inhibiting activity, that  
N,N-disubstitution of the terminal amino moiety by two methyl groups is crucial for a high antifungal 
effect. This fact corresponds to results obtained by Opletalova et al. [26]. 
2.3.3. In Vitro Antiproliferative Activity 
The antiproliferative activity of all of the compounds was examined against the human colon cancer 
(HCT-116) cell line using an MTS assay. The HCT-116 p53 wild type cell line was chosen on the 
basis of our former experience and some results on the activity of quinoline-based thiosemicarbazones 
that was published recently. Namely, compounds 4a–l have been tested previously for their wide-
ranging anticancer activity [34]. The antiproliferative activity of the compounds evaluated was 
assessed using Doxorubicin as a reference compound. In general, quinoline-based thiosemicarbazones 
4 seem to have a much better anticancer activity than halogenophenyl compounds 3. Thus, the 
quinoline nucleus can be defined as being crucial for antiproliferative activity. A more detailed 
analysis of the anticancer activity of quinoline-based thiosemicarbazone is available [34]. 
Benzylidenethiosemicarbazones were much less active against the cells tested. Compound 3a appeared 
to be the most active in this assay. Nevertheless, some more general conclusions can be drawn from 
the gathered data. Dichlorosubstituted compounds are in general more active than monobromo 
equivalents. The free amino group or substitution pattern with small substituents such as methyl or 
ethyl are favorable for activity. According to our former results the chelating ability of the compounds 
may be one of the prerequisites of the antiproliferative activity. In this study we have measured the 
UV-VIS spectra of the compounds in presence of various concentration of Fe3+ cations to observe its 
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chelating potency (supplementary material). Isosbestic points are observable in case of more active 
compounds like 4a–l series while in 3a–o only minor or no interaction between ligand and metal can 
be noticed. Compound 4b one of the most active against HCT-116 cells and in antifungal assays gave 
clear isosbestic points at 375 nm. However as 4j give also two points at 330 and 385 nm, iron 
chelating ability should be regarded only as one of the factor influencing the biological activity. 
3. Experimental 
3.1. General 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) or Princeton Chemicals 
Ltd. (Luton, Bedfordshire, UK). Kieselgel 60, 0.040–0.063 mm (Merck, Darmstadt, Germany) was 
used for the column chromatography. Syntheses were performed in a CEM DISCOVERY microwave 
reactor (Matthews, NC, USA) with temperature and pressure control. TLC experiments were 
performed on alumina-backed silica gel 40 F254 plates (Merck, Darmstadt, Germany). The plates were 
illuminated under UV (254 nm) and evaluated in an iodine vapor. The melting points were determined 
on an Optimelt MPA100 instrument (SRS, USA) and are uncorrected. Infrared (IR) spectra were 
recorded on a Smart MIRacle™ ATR ZnSe for Nicolet™ Impact 410 FT-IR spectrometer (Thermo 
Fisher Scientific, Waltham, MA, USA). The spectra were obtained by the accumulation of 256 scans with 
2 cm−1 resolution in the region of 4000–600 cm−1. All 1H and 13C-NMR spectra were recorded on a 
Bruker Avance III 400 MHz FT-NMR spectrometer (400 MHz for 1H and 100 MHz for 13C, 
BrukerBioSpin Comp., Karlsruhe, Germany). Chemicals shifts are reported in ppm () using internal 
Si(CH3)4 as the reference with diffuse, easily exchangeable signals being omitted. HR-MS (EI) 
analysis was performed on a Finnigan MAT95 spectrometer (ThermoFinnigan, San Jose, CA, USA) 
for all new compounds. 
3.2. Synthesis 
3.2.1. General Procedure for Synthesis of Thiosemicarbazones 3a–o 
Equimolar quantities of an appropriate thiosemicarbazide and benzaldehyde derivative were mixed 
and 2 drops of glacial acetic acid were added. The resulting mixture was heated in a microwave reactor 
at 85 °C for 12 min (max microwave power 75 W). After cooling, the precipitated solids were filtered 
off, washed with ether and crystallized from methanol. The compounds 3a–o studied are presented  
in Table 1. 
(E)-2-(2,3-Dichlorobenzylidene)hydrazinecarbothioamide (3a). Yield: 78%, 1H-NMR (d6-DMSO,  
400 MHz, ppm): 11.69 (bs, 1H, NH), 8.49 (s, 1H, CH), 8.36 (s, 1H, NH), 8.30 (d, J = 8.0 Hz, 1H, 
ArH), 8.18 (bs, 1H, NH), 7.66 (d, J = 7.9 Hz, 1H, ArH), 7.38 (t, J = 8.0 Hz, 1H, ArH). 13C-NMR  
(d6-DMSO, 100 MHz, ppm): 178.8, 138.2, 134.2; 132.6, 131.6, 131.2, 128.5, 126.5. MP: 226–227 °C 
HR-MS (EI): 246.9745 (calc. for C8H7Cl2N3S: 246.9738). 
(E)-2-(2,3-Dichlorobenzylidene)-N-methylhydrazinecarbothioamide (3b). Yield: 74%, 1H-NMR  
(d6-DMSO, 400 MHz, ppm): 11.76 (s, 1H, NH), 8.68 (d, J = 4.4 Hz, 1H, NH), 8.49 (s, 1H, CH), 8.29 
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(d, J = 8.0 Hz, 1H, ArH), 7.67 (d, J = 7.9 Hz, 1H, ArH), 7.41 (t, J = 7.9 Hz, 1H, ArH), 3.02 (d, J = 4.5 Hz, 
CH3). 13C-NMR (d6-DMSO, 100 MHz, ppm): 178.5, 137.7, 134.5, 132.5, 131.4, 131.3, 128.4, 126.2, 
31.4. MP: 223–224 °C, HR-MS (EI): 260.9891 (calc. for C9H9Cl2N3S: 260.9894). 
(E)-2-(2,3-Dichlorobenzylidene)-N,N-dimethylhydrazinecarbothioamide (3c). Yield: 69%, 1H-NMR 
(d6-DMSO, 400 MHz, ppm): 11.27 (s, 1H, NH), 8.64 (s, 1H, CH), 7.92 (dd, J1 = 7.9 Hz, J2 = 1.4 Hz, 
1H, ArH), 7.66 (dd, J1 = 7.9 Hz, J2 = 1.5 Hz, 1H, ArH), 7,42 (t, J = 8.0 Hz, 1H, ArH), 3.31 (s, 6H, 
CH3). 13C-NMR (d6-DMSO, 100 MHz, ppm): 180.8, 140.0, 134.7, 132.7, 131.5, 131.0, 128.8, 125.7, 
42.4. MP: 145–146 °C, HR-MS (EI): 275.0047 (calc. for C10H11Cl2N3S: 275.0051). 
(E)-2-(2,3-Dichlorobenzylidene)-N-ethylhydrazinecarbothioamide (3b). Synthesis and more detailed 
analysis of the structure is available [44]. Yield: 67%, 1H-NMR (d6-DMSO, 400 MHz, ppm): 11.70 (s, 
1H, NH), 8.70 (m, 1H, NH), 8.49 (s, 1H, CH), 8.31 (d, J = 7.9 Hz, 1H, ArH), 7.67(d, J = 7.9 Hz, 1H, 
ArH), 7.41 (t, J = 7.9 Hz, 1H, ArH), 3.70–3.52 (m, 2H, CH2), 1.16 (t, J = 7.0 Hz, 3H, CH3). 13C-NMR 
(d6-DMSO, 100 MHz, ppm): 177.4, 137.6, 134.4, 132.5, 131.5, 131.3, 128.5, 126.02, 38.9, 14.7. MP: 
213–214 °C HR-MS (EI): 275.0054 (calc. for C10H11Cl2N3S: 275.0051), IR: 3349 (NH), 3142 (PhH), 
2983 (CH), 1584 (C=N), 1542 (C-N), 1520 (CH), 1452 (CH/NH), 1416 (CH3), 1311 (CNH), 1264 
(C/NH), 1160(N-N), 1108 (), 1042 (NH), 929 , 906 (CS), 782 (CS), 737, 704 (ring), 626 (C-N). 
UV-VIS (methanol; log): 323.0 (3.96), 237.0 (3.67), 204.0 (3.91). 
(E)-2-(2,3-dichlorobenzylidene)-N-phenylhydrazinecarbothioamide (3b). Yield: 79%, 1H-NMR  
(d6-DMSO, 400 MHz, ppm): 12.08 (bs, 1H, NH), 10.26 (s, 1H, NH), 8.62 (s, 1H, CH), 8.47 (d,  
J = 9.3 Hz, 1H, ArH), 7.68 (t, J = 7.1 Hz, 1H, ArH), 7.55 (d, J = 7.7 Hz, 2H, ArH), 7.43–7.37 (m, 3H, 
ArH), 7.23 (t, J = 7.6 Hz, 1H, ArH). 13C-NMR (d6-DMSO, 100 MHz, ppm): 176.9, 139.5, 138.9, 
134.3, 132.6, 131.8, 131.5, 128.6, 126.8, 126.6, 126.0. MP: 203–204 °C, HR-MS (EI): 323.0066  
(calc. for C14H11Cl2N3S: 323.0051). 
(E)-2-(3,4-Dichlorobenzylidene)hydrazinecarbothioamide (3f). Synthesis and more detailed analysis 
of the structure is available [44]. Yield: 85%, 1H-NMR (d6-DMSO, 400 MHz, ppm): 11.56 (s, 1H, 
NH), 8.28 (s, 1H, NH), 8.24 (d, J = 1.7 Hz, 1H, ArH), 8.00 (s, 1H, CH), 7.72 (dd, J = 8.4, 1.8 Hz, 1H, 
ArH), 7.64 (d, J = 8.3 Hz, 1H, ArH). 13C-NMR (d6-DMSO, 100 MHz, ppm): 178.7, 139.9, 135.6, 
132.3, 132.3, 131.2, 128.7, 128.2. MP: 205–206 °C [34]. IR: 3395, 3256 (NH), 3154 (PhH), 2992 
(CH), 1596 (NH2), 1538 (C=N), 1471 (CH/NH), 1291 NH), 1129 (N-N), 1100 (), 1065 (NH), 
1031(ring), 938(CH), 870, 823 (CS), 625 C-N). UV-VIS (MeOH; log : 320.0 (4.01), 239.0 (3.63), 
203.0 (3.92). 
(E)-2-(3,4-Dichlorobenzylidene)-N-methylhydrazinecarbothioamide (3f). Yield: 89% 1H-NMR  
(d6-DMSO, 400 MHz, ppm): 11.63 (s, 1H, NH), 8.68 (d, J = 3.8 Hz, 1H, NH), 8.20 (s, 1H, CH), 8.00 
(s, 1H, ArH), 7.69 (dd, J1 = 23.9, J2 = 8.3 Hz, 2H), 3.03 (d, J = 4.3 Hz, 3H). 13C-NMR (d6-DMSO, 100 
MHz, ppm): 178.4, 139.4, 135.7, 132.2, 132.2, 131.2, 128.5, 128.1, 31.62. MP: 202–203 °C.  
HR-MS (EI): 260.9902 (calc. for C9H9Cl2N3S: 260.9894). 
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(E)-2-(3,4-Dichlorobenzylidene)-N,N-dimethylhydrazinecarbothioamide (3h). Yield: 79% 1H-NMR 
(d6-DMSO, 400 MHz, ppm): 11.12 (s, 1H, NH), 8.17 (s, 1H, CH), 7.86 (d, J = 1.7 Hz, 1H, ArH),  
7.70–7.63 (m, 1H, ArH), 3.30 (s, 6H, CH3). 13C-NMR (d6-DMSO, 100 MHz, ppm): 181.0, 141.5, 
136.0, 132.1, 132.0, 131.5, 128.4, 127.0, 42.5. MP: 138–139 °C HR-MS (EI): 275.0048 (calc. for 
C10H11Cl2N3S: 275.0051). 
(E)-2-(3,4-Dichlorobenzylidene)-N-ethylhydrazinecarbothioamide (3i). Yield: 83%, 1H-NMR  
(d6-DMSO, 400 MHz, ppm): 11.56 (s, 1H, NH), 8.73 (t, J = 5.7 Hz, 1H, NH), 8.19 (d, J = 1.7 Hz, 1H, 
ArH), 8.00 (s, 1H, CH), 7.78–7.70 (m, 1H, ArH), 7.67 (d, J = 8.3 Hz, 1H), 3.61 (m, 2H, CH2), 1.16  
(t, J = 7.1 Hz, 3H, CH3). 13C-NMR (d6-DMSO, 100 MHz, ppm): 177.3, 139.5, 135.6, 132.2, 132.2, 131.3, 
128.6, 128.1, 38.8, 15.0. MP: 177–178 °C, HR-MS (EI): 275.0058 (calc. for C10H11Cl2N3S: 275.0051). 
(E)-2-(3,4-Dichlorobenzylidene)-N-phenylhydrazinecarbothioamide (3j). Yield: 86%, 1H-NMR  
(d6-DMSO, 400 MHz, ppm): 11.96 (s, 1H, NH), 10.27 (s, 1H, NH), 8.35 (s, 1H, NH), 8.12 (s, 1H, Ar), 
7.82 (dd, J = 8.4, 1.7 Hz, 1H, ArH), 7.68 (d, J = 8.3 Hz, 1H, ArH), 7.53 (d, J = 7.7 Hz, 2H, Ph), 7.39 
(t, J = 7.8 Hz, 2H, Ph), 7.24 (t, J = 7.4 Hz, 1H, Ph). 13C-NMR (d6-DMSO, 100 MHz, ppm): 176.9, 
140.6, 139.5, 135.4, 132.5, 132.3, 131.2, 128.9, 128.6, 126.9, 126.1. MP: 200–201 °C [28]. 
(E)-2-(4-Bromobenzylidene)hydrazinecarbothioamide (3k). Yield: 69% 1H-NMR (d6-DMSO,  
400 MHz, ppm): 11.48 (s, 1H, NH), 8.23 (s, 1H, NH), 8.07 (s, 1H, NH), 8.02 (s, 1H, CH), 7.77 (d,  
J = 8.5 Hz, 2H, ArH), 7.59 (d, J = 8.5 Hz, 2H, ArH). 13C-NMR (d6-DMSO, 100 MHz, ppm): 178.6, 
141.4, 134.0, 132.1, 129.6, 123.5. MP: 222 °C [48]. 
(E)-2-(4-bromobenzylidene)-N-methylhydrazinecarbothioamide (3l). Yield: 72%; 1H-NMR (d6-
DMSO, 400 MHz, ppm): 11.54 (s, 1H, NH), 8.57 (d, J = 4.0 Hz, 1H), 8.01 (s, 1H, CH), 7.77 (d,  
J = 8.3 Hz, 2H, ArH), 7.61 (d, J = 8.4 Hz, 2H, ArH), 3.02 (d, J = 4.4 Hz, 3H, CH3). 13C-NMR  
(d6-DMSO, 100 MHz, ppm): 178.3, 140.8, 134.1, 132.0, 129.4, 123.4, 31.2. MP: 204–205 °C [49]. 
(E)-2-(4-bromobenzylidene)-N,N-dimethylhydrazinecarbothioamide (3m). Yield: 61%, 1H-NMR  
(d6-DMSO, 400 MHz, ppm): 11.00 (s, 1H, NH), 8.17 (s, 1H, CH), 7.71–7.45 (m, 4H, ArH), 3.29  
(s, 6H, CH3). 13C-NMR (d6-DMSO, 100 MHz, ppm): 181.0, 143.0, 134.4, 132.2, 129.0, 123.1, 42.6. 
MP: 150–151 °C [50]. 
(E)-2-(4-Bromobenzylidene)-N-ethylhydrazinecarbothioamide (3n). Synthesis and more detailed 
analysis of the structure is available [44]. Yield: 78%, 1H-NMR (d6-DMSO, 400 MHz, ppm): 11.47  
(s, 1H, NH), 8.61 (t, J = 5.8 Hz, 1H, NH), 8.02 (s, 1H, CH), 7.77 (d, J = 8.5 Hz, 2H, ArH), 7.61  
(d, J = 8.5 Hz, 2H, ArH), 3.63–3.56 (m, J = 7.0 Hz, 2H, CH2), 1.15 (t, J = 7.1 Hz, 3H, ArH).  
13C-NMR (d6-DMSO, 100 MHz, ppm): 177.2, 140.9, 134.1, 132.0, 129.6, 123.4, 38.8, 15.0. MP:  
199–200 °C, HR-MS(EI): 284.9944 (calc. for C10H12BrN3S Exact Mass: 284,9935), IR: 3363 NH), 
3139 PhH), 2980 CH), 1589 C=N), 1538 C-N), 1522 CH), 1485 CH/NH), 1397 CNH), 1293 
(CNH), 1104 N-N), 1081  1066 NH), 1006 ring), 921 CH), 816 CS), 623 C-N).  
UV-VIS (MeOH, log : 330 (sh), 319.5 (3.98), 233.0 (3.65), 218 (sh), 202.5 (3.91). 
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(E)-2-(4-bromobenzylidene)-N-phenylhydrazinecarbothioamide (3o). Yield: 68%, 1H-NMR  
(d6-DMSO, 400 MHz, ppm): 11.88 (s, 1H, NH), 10.17 (s, 1H, NH), 8.13 (s, 1H, CH), 7.89 (d,  
J = 8.5 Hz, 2H, ArH), 7.63 (d, J = 8.5 Hz, 2H, ArH), 7.56 (d, J = 7.6 Hz, 2H, Ph), 7.38 (t, J = 7.8 Hz, 
2H, Ph), 7.22 (t, J = 7.4 Hz, 1H, Ph). 13C-NMR (d6-DMSO, 100 MHz, ppm):176.6, 142.0, 139.5, 
133.9, 132.1, 130.0, 128.5, 126.5, 125.9, 123.7. MP: 197–198 °C [49]. 
3.2.2. General Procedure for the Synthesis of Thiosemicarbazones 4a–l 
All quinoline-based thiosemicarbazones were prepared according to a recently published procedure 
[34]. Equimolar quantities of an appropriate thiosemicarbazide and benzaldehyde derivative were 
mixed and 2 drops of glacial acetic acid were added. The resulting mixture was heated in a microwave 
reactor at 85 °C for 12 min (max microwave power 75 W). After cooling, the precipitated soli were 
filtered and washed with ether and crystallized from methanol. The compounds 4a–l studied are presented 
in Table 2.  
3.3. Lipophilicity Determination Using HPLC (Capacity Factor k/Calculated log k) 
A Waters Alliance 2695 XE HPLC separation module and a Waters Photodiode Array Detector 
2996 (Waters Corp., Milford, MA, USA) were used. A Symmetry® C18 5 μm, 4.6  250 mm, Part No. 
WAT054275 (Waters Corp.) chromatographic column was used. The HPLC separation process was 
monitored using Empower™ 2 Chromatography Data Software, Waters 2009 (Waters Corp.). A 
mixture of MeOH p.a. (55%) and H2O-HPLC-Mili-Q Grade (45%) was used as a mobile phase. The 
total flow of the column was 0.9 mL/min, injection volume 30 μL, column temperature 30 °C and 
sample temperature 10 °C. A detection wavelength of 210 nm was chosen. A KI methanolic solution 
was used for the determination of dead time (tD). Retention times (tR) were measured in minutes. The 
capacity factors k were calculated using the Empower™ 2 Chromatography Data Software according 
to the formula k = (tR − tD)/tD, where tR is the retention time of the solute, whereas tD denotes the dead 
time obtained using an unretained analyte. Log k, calculated from the capacity factor k, is used as the 
lipophilicity index converted to log P scale. The log k values of the individual compounds are shown 
in Tables 1 and 2. 
3.4. Lipophilicity Calculations 
Log P, i.e., the logarithm of the partition coefficient for n-octanol/water, was calculated using  
the programs ChemOffice [45] and ACD/LogP [46]. Clog P values (the logarithm of n-octanol/water 
partition coefficient based on established chemical interactions) were generated using ChemOffice 
software [45]. The results are shown in Tables 1 and 2. 
3.5. Study of the Inhibition Photosynthetic Electron Transport (PET) in Spinach Chloroplasts 
Chloroplasts were prepared from spinach (Spinacia oleracea L.) according to Masarovicova and 
Kralova [51]. The inhibition of the photosynthetic electron transport (PET) in spinach chloroplasts was 
determined spectrophotometrically (Genesys 6, Thermo Fisher Scientific, Waltham, MA, USA) using 
an artificial electron acceptor 2,6-dichlorophenol-indophenol (DCIPP) according to Kralova et al. [52] 
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and the rate of photosynthetic electron transport was monitored as a photoreduction of DCPIP. The 
measurements were carried out in a phosphate buffer (0.02 mol/L, pH 7.2) containing sucrose  
(0.4 mol/L), MgCl2 (0.005 mol/L) and NaCl (0.015 mol/L). The chlorophyll content was 30 mg/L in these 
experiments and the samples were irradiated (~100 W/m2 with 10 cm distance) with a halogen lamp 
(250 W) using a 4 cm water filter to prevent warming of the samples (suspension temperature 22 °C). 
The compounds studied were dissolved in DMSO due to their limited water solubility. The applied 
DMSO concentration (up to 4%) did not affect the photochemical activity in the spinach chloroplasts. 
The inhibitory efficiency of the compounds studied was expressed by IC50 values, i.e., by the molar 
concentration of the compounds that caused a 50% decrease in the oxygen evolution rate relative to the 
untreated control. The comparable IC50 value for a selective herbicide 3-(3,4-dichlorophenyl)-1,1-
dimethylurea, DCMU (Diurone®) was about 1.9 μmol/L. The results are summarized in Table 3. 
3.6. In Vitro Antifungal Susceptibility Testing 
The broth microdilution test [53–55] was used for the assessment of the in vitro antifungal activity 
of the synthesized compounds against Candida albicans ATCC 44859 (CA), Candida tropicalis  
156 (CT), Candida krusei ATCC 6258 (CK), Candida glabrata 20/I (CG), Trichosporon beigelii  
1188 (TB), Aspergillus fumigatus 231 (AF), Absidia corymbifera 272 (AC), and Trichophyton 
mentagrophytes 445 (TM). Fluconazole (FLU) was used as the standard since it is a clinically used 
antimycotic drug. The procedure was performed using a twofold dilution of the compounds in RPMI 
1640 (Sevapharma a.s., Prague, Czech Republic) buffered to pH 7.0 with 0.165 mol of 3-morpholino-
propane-1-sulfonic acid (MOPS, Sigma, Prague, Czech Republic). The final concentrations of the 
compounds ranged from 500 to 0.975 μmol/L. Drug-free controls were included. The determination of 
minimum inhibitory concentration (MIC) was performed according to the Clinical and Laboratory 
Standards Institute (CLSI, formerly NCCLS) reference protocol M27-A2 for yeasts (IC80 value) and 
M38-A for moulds (IC50 value). IC80 and IC50 were defined as an 80% resp. 50% or greater reduction 
in growth in comparison with the control. The values of MICs were determined after 24 and 48 h of 
static incubation at 35 °C. The final MICs for T. mentagrophytes, were determined after 72 and 120 h 
of incubation. The results are summarized in Table 3. 
3.7. Cell Culture and in Vitro Antiproliferative Activity 
The human colon cancer cell line HCT116 with the wild type p53 gene (p53+/+) were obtained from 
Maria Sklodowska-Curie Memorial Cancer Center in Gliwice, Poland. Briefly, the cells were seeded 
in 96-well plates (3 × 103 cells/well) in cellular proliferation assays 24 h before the addition of the 
chelators. The assay was performed following a 72 h incubation with varying concentrations of the 
agents. Each compound was tested in triplicate in a single experiment with each experiment being 
repeated 3 times. After 72 h incubation with the compounds being investigated, 20 µL of MTS 
solution was added to each well (100 µL) and incubated for 1 h at 37 °C. The optical densities of the 
samples were analyzed at 490 nm. Results were expressed as a percentage of the control. The 
inhibitory concentration (IC50) was defined as the compound concentration necessary to reduce the 
absorbance to 50% of the untreated control. The results are summarized in Table 3.  
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4. Conclusions 
A series of fifteen substituted benzylidenethiosemicarbazones and twelve substituted 
quinolinylvinylthiosemicarbazones were designed, prepared and characterized. The synthesis of these 
compounds was carried out in microwave conditions, which improves the yield and purity of products 
isolated. The prepared compounds were tested for their ability to inhibit photosynthetic electron 
transport (PET) in spinach chloroplasts (Spinacia oleracea L.), for their antifungal activity and for 
their anticancer activity against human colon cancer. All of the compounds were primarily designed as 
potential thiosemicarbazone-based iron chelators. All of the compounds discussed showed moderate 
PET inhibition as well as an antifungal effect. (E)-2-(quinolin-2-ylvinyl)-N,N-dimethylhydrazine-
carbothioamide (4b) expressed the strongest activity among all of the compounds tested; it was 
comparable to or more active than fluconazole against Aspergillus fumigatus, Absidia corymbifera, 
Candida tropicalis and Candida krusei. Compounds 4b and 4e expressed micromolar antiproliferative 
activity better than standard doxorubicin. According to the results, the quinoline nucleus and the  
N,N-dimethylhydrazinecarbothioamide chain can be considered as basic structural fragments for high 
antiproliferative and antifungal activity. Iron chelation was assumed in UV-VIS spectra analysis. 
According to the results we can concluded that iron chelating ability of the compounds is one of 
factors necessary for the activity. 
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